Timothy C Rodell

US Patent:

6685917, Feb 3, 2004

Filed:

Nov 21, 2001

Appl. No.:

09/993383

Inventors:

Gary J. Rosenthal - Louisville CO
Jeffrey B. Etter - Boulder CO
Timothy C. Rodell - Aspen CO
Wren H. Schauer - Boulder CO
Adrian Samaniego - Louisville CO

Assignee:

RxKinetix, Inc. - Louisville CO

International Classification:

A61K 31195

US Classification:

424 49

Abstract:

This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.

US Patent:

7767197, Aug 3, 2010

Filed:

Jun 22, 2001

Appl. No.:

09/888235

Inventors:

Joan P. Blonder - Lafayette CO, US
Claire M. Coeshott - Denver CO, US
Timothy C. Rodell - Aspen CO, US
Wren H. Schauer - Boulder CO, US
Gary J. Rosenthal - Louisville CO, US

Assignee:

Endo Pharmaceuticals Colorado LLC - Chadds Ford PA

International Classification:

A61A 31/745
A61A 31/00

US Classification:

424 7817, 424 7818, 424 7819, 424 7831, 4242041

Abstract:

The present invention provides an immunogen composition and methods for using the same for the development of immunity, and particularly at mucosal sites in a mammal, thereby providing immunity at the site of entry for many major pathogenic organisms and also systemic immunity. The immunogen composition includes an antigen, a biocompatible polymer, and a liquid vehicle, with the biocompatible polymer and liquid vehicle being present in such proportions and interacting in such a way that the immunogen composition exhibits reverse-thermal viscosity behaviour. A delivery vehicle composition including a drug other than an antigen is also provided. Methods are provided for delivering the compositions of the invention to a host.

US Patent:

8501167, Aug 6, 2013

Filed:

Jan 17, 2008

Appl. No.:

12/531876

Inventors:

David Apelian - Boonton Township NJ, US
Alex Franzusoff - Denver CO, US
Timothy C. Rodell - Aspen CO, US

Assignee:

GlobeImmune, Inc. - Louisville CO

International Classification:

A61K 39/00
A61K 31/131
A61K 31/136
A61K 31/166
A61K 31/167

US Classification:

424 9321, 424 9351, 4241851, 4241921, 4242771, 514257, 514275, 514279, 514280, 514577, 514579, 514617

Abstract:

Provided herein are compositions and methods for targeted ablation of mutational escape in the face of cancer therapeutic agents. Compositions comprising the yeast-based vehicles are used in combination with other cancer therapeutic agents.

US Patent:

20040141949, Jul 22, 2004

Filed:

Dec 4, 2003

Appl. No.:

10/728277

Inventors:

Gary Rosenthal - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US

International Classification:

A61K038/19
A61K038/05
A61K031/198

US Classification:

424/085100, 514/018000, 514/562000

Abstract:

This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.

US Patent:

20040258702, Dec 23, 2004

Filed:

Apr 21, 2004

Appl. No.:

10/828842

Inventors:

Joan Blonder - Lafayette CO, US
Claire Coeshott - Denver CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Gary Rosenthal - Lafayette CO, US

International Classification:

A61K039/00
A61K039/38
A61K045/00
A61K047/00

US Classification:

424/184100

Abstract:

We have developed a vaccine delivery system based on the non-ionic block copolymer, PluronicF127 (F127), combined with selected immunomodulators. F127-based matrices are characterized by a phenomenon known as reverse thermogelation, whereby the formulation undergoes a phase transition from liquid to gel upon reaching physiological temperatures. Protein antigens (tetanus toxoid (TT), diphtheria toxoid (DT) and anthrax recombinant protective antigen (rPA) were formulated with F127 in combination with CpG motifs or chitosan, as examples of immunomodulators, and were compared to more traditional adjuvants in mice. IgG antibody responses were significantly enhanced by the F127/CpG and F127/chitosan combinations compared to antigens mixed with CpGs or chitosan alone. In addition, the responses were significantly greater than those elicited by aluminum salts. Furthermore, the functional activity of these antibodies was demonstrated using either in vivo tetanus toxin challenge or an anthrax lethal toxin neutralization assay. These studies suggest that a block-copolymer approach could enhance the delivery of a variety of clinically useful antigens in vaccination schemes.

US Patent:

20070014860, Jan 18, 2007

Filed:

Sep 22, 2006

Appl. No.:

11/525752

Inventors:

Gary Rosenthal - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US

International Classification:

A61K 9/14

US Classification:

424486000

Abstract:

A method for treatment of esophagitis is disclosed in which a therapeutic composition is introduced into the esophagus to contact a mucosal surface within the esophagus. The pharmaceutical composition comprises a reverse-thermal gelation polyoxyalkylene block copolymer, a pharmaceutical substance and a pharmaceutical substance selected from the group consisting of glutathione and a precursor for glutathione biosynthesis.

US Patent:

20070014861, Jan 18, 2007

Filed:

Sep 22, 2006

Appl. No.:

11/525983

Inventors:

Gary Rosenthal - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US

International Classification:

A61K 38/05
A61K 31/385
A61K 9/14

US Classification:

424486000, 514018000, 514440000

Abstract:

A method for treatment of proctitis is disclosed in which a therapeutic composition is introduced into the rectum to contact a mucosal surface within the rectum. The pharmaceutical composition comprises a reverse-thermal gelation polyoxyalkylene block copolymer, a pharmaceutical substance and a pharmaceutical substance selected from the group consisting of glutathione and a precursor for glutathione biosynthesis.

US Patent:

20070071824, Mar 29, 2007

Filed:

Sep 29, 2006

Appl. No.:

11/540357

Inventors:

Gary Rosenthal - Louisville CO, US
Jeffrey Etter - Boulder CO, US
Timothy Rodell - Aspen CO, US
Wren Schauer - Boulder CO, US
Adrian Samaniego - Louisville CO, US

International Classification:

A61K 31/198
A61K 9/14

US Classification:

424486000, 514562000

Abstract:

This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.